双PI3K/MTOR抑制剂PF-04691502联合放疗在头颈部肿瘤中的抗肿瘤活性
该研究在两种低代次头颈鳞癌(HNSCC)模型中评估口服双PI3K/MTOR抑制剂PF-04691502联合临床相关分割放疗的活性。结果显示PF-04691502在源自原发癌的UT-SCC-14模型中与放疗协同,但在源自淋巴结复发的UT-SCC-15模型中无效。两模型在突变负荷、PI3K/AKT/MTOR通路变异及组成性活性上存在关键差异,可解释疗效差异。
要点
- PF-04691502联合分割放疗在UT-SCC-14模型中显示协同作用。
- UT-SCC-15模型对联合治疗无效,伴更高突变负荷及PI3K/AKT/MTOR通路变异增多。
- 疗效差异提示需对HNSCC进行分子分型以筛选获益人群。
核心结论
- PF-04691502联合放疗在部分HNSCC中具有治疗前景,但非响应肿瘤需分子特征分析与替代策略。
研究设计与样本
- 在两种特征明确的低代次HNSCC模型(UT-SCC-14源自原发癌,UT-SCC-15源自淋巴结复发)中研究PF-04691502联合临床相关分割放疗的活性。
主要发现
- PF-04691502与放疗在UT-SCC-14模型中协同,但在UT-SCC-15模型中无效。
- UT-SCC-15细胞系具有更高突变负荷、PI3K/AKT/MTOR通路变异增多、PI3K、AKT1和2及MTOR组成性活性增加,且治疗无法抑制关键磷酸化事件。
临床怎么用
- PF-04691502联合放疗可能适用于经分子特征筛选的HNSCC患者。
- 对潜在非响应HNSCC需基于分子特征探索替代治疗策略。
局限性
- 研究仅基于两种低代次HNSCC细胞系模型,结论需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Head and neck squamous cell carcinoma (HNSCC) remains a clinical challenge where new treatments are required to supplement the current-standard-of care of concurrent chemoradiation. The PI3K/AKT/MTOR pathway has been identified from several next generation DNA sequencing studies to be commonly altered and activated in HNSCC. MATERIAL AND METHODS: In this study we investigated the activity of PF-04691502, an orally active ATP-competitive, dual inhibitor of PI3K and mTOR, in combination with a clinically relevant fractionated radiation treatment in two contrasting, well characterized, low passage HNSCC models. RESULTS: We found that PF-04691502 combined synergistically with radiation in the UT-SCC-14 model derived from a primary cancer but was ineffective in the UT-SCC-15 model which was derived from a nodal recurrence. Further examination of the status of key signaling pathways combined with next generation DNA sequencing of a panel of 160 cancer-associated genes revealed crucial differences between the two models that could account for the differential effect. The UT-SCC-15 cell line was characterized by a higher mutational burden, an excess of variants in the PI3K/AKT/MTOR pathway, increased constitutive activity of PI3K, AKT1 and 2 and MTOR and an inability to inhibit key phosphorylation events in response to the treatments. CONCLUSION: This study clearly highlights the promise of agents such as PF-04691502 in selected HNSCCs but also emphasizes the need for molecular characterization and alternative treatment strategies in non-responsive HNSCCs.
引用
- Tonlaar N, Galoforo S, Thibodeau BJ, et al. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer. Radiother Oncol. 2017. PMID: 28823407. doi:10.1016/j.radonc.2017.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。